Swiss Lonza’s Pharma Biotech Business Drives Strong H1 2020 Group Sales Growth and Margin Improvement

Strong operational performance maintained during COVID-19; sites remained open and protection of employees continues to be a top priority Landmark ten-year collaboration with Moderna on the mRNA1 platform. The current focus is to manufacture an mRNA-based vaccine (mRNA-1273) for the novel coronavirus Group sales growth of 7.7 % and resilient CORE EBITDA margin of 29.1 … More Swiss Lonza’s Pharma Biotech Business Drives Strong H1 2020 Group Sales Growth and Margin Improvement